Binding of huperzine A and galanthamine to acetylcholinesterase, based on ONIOM method.

UNLABELLED Binding energy calculations of huperzine A (HUP A) and galanthamine (GAL) to the binding pocket of the acetylcholinesterase enzyme (AChE) were studied. It was found that hydrogen bond formation and particular hydrogen π interactions exhibit the most significant contributions to the binding interaction of HUP A with Trp84 (W84) and Tyr130 (Y130), whereas no hydrogen bond was detected with Y130 of GAL binding. The interaction energies, calculated at the MP2 level between drugs and residues, demonstrate that the attractive interactions between GAL and residues at positions 84 and 130 were less than those for HUP A by 1.6 and 7.7 kcal·mol(-1), respectively. In addition, ONIOM3 results show that the binding energies of HUP A per pocket (-28.4 kcal mol(-1)) are higher than for GAL per pocket (-17.0 kcal·mol(-1)). The detailed understanding of these interactions can be useful for the design of specific inhibitors for the AChE binding site. FROM THE CLINICAL EDITOR The more efficient and specific inhibition of acetylcholinesterase may provide an enhanced treatment strategy in Alzheimer's disease compared to the currently available inhibitors. This study discusses interactions of the enzyme binding site with two ligands. The results may pave the way to the development of more potent inhibitors.

[1]  Marc Tessier-Lavigne,et al.  APP binds DR6 to trigger axon pruning and neuron death via distinct caspases , 2009, Nature.

[2]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[3]  S. F. Boys,et al.  The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors , 1970 .

[4]  Christian Sorg,et al.  Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. , 2006, Age and ageing.

[5]  Jans H. Alzate-Morales,et al.  A computational ONIOM model for the description of the H-bond interactions between NU2058 analogues and CDK2 active site , 2009 .

[6]  K. Morokuma,et al.  Performance Evaluation of the Three-Layer ONIOM Method:  Case Study for a Zwitterionic Peptide. , 2006, Journal of chemical theory and computation.

[7]  C. Geula,et al.  Cholinesterases and the pathology of Alzheimer disease. , 1995, Alzheimer disease and associated disorders.

[8]  Yuan-Ping Pang,et al.  Structure of acetylcholinesterase complexed with the nootropic alkaloid, (–)-huperzine A , 1997, Nature Structural Biology.

[9]  R. Sequeira.  Central nervous system stimulants and drugs that suppress appetite , 1998 .

[10]  Mahmud Tareq Hassan Khan.  Molecular interactions of cholinesterases inhibitors using in silico methods: current status and future prospects. , 2009, New biotechnology.

[11]  G. Hu,et al.  Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex , 1999, Neuroscience Letters.

[12]  Hualiang Jiang,et al.  Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. , 2005, Journal of medicinal chemistry.

[13]  H. Zhang,et al.  Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. , 2006, Trends in pharmacological sciences.

[14]  G. Campiani,et al.  Conformational flexibility in the peripheral site of Torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor. , 2006, Journal of the American Chemical Society.

[15]  Mayuso Kuno,et al.  ONIOM-BSSE scheme for H⋯π system and applications on HIV-1 reverse transcriptase , 2006 .

[16]  Mayuso Kuno,et al.  Binding energy analysis for wild‐type and Y181C mutant HIV‐1 RT/8‐Cl TIBO complex structures: Quantum chemical calculations based on the ONIOM method , 2005, Proteins.

[17]  Nicola Vanacore,et al.  Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.

[18]  Mayuso Kuno,et al.  Theoretical investigation on nevirapine and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method , 2003 .

[19]  A. Mutlib,et al.  Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. , 1996, The Journal of pharmacology and experimental therapeutics.

[20]  J. Ellis.  Cholinesterase Inhibitors in the Treatment of Dementia , 2005, The Journal of the American Osteopathic Association.

[21]  J L Sussman,et al.  Structure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution , 1999, FEBS letters.

[22]  Hans Peter Lüthi,et al.  Interaction energies of van der Waals and hydrogen bonded systems calculated using density functional theory: Assessing the PW91 model , 2001 .

[23]  J L Sussman,et al.  X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. , 2002, Biochemistry.

[24]  Keiji Morokuma,et al.  ONIOM and Its Applications to Material Chemistry and Catalyses , 2003 .

[25]  Peter Pulay,et al.  CAN (SEMI) LOCAL DENSITY FUNCTIONAL THEORY ACCOUNT FOR THE LONDON DISPERSION FORCES , 1994 .

[26]  N. Greig,et al.  Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. , 2005, Current Alzheimer research.